RAC1b overexpression correlates with poor prognosis in KRAS/BRAF WT metastatic colorectal cancer patients treated with first-line FOLFOX/XELOX chemotherapy.

doi:10.1016/j.ejca.2014.04.019

Article

RAC1b overexpression correlates with poor prognosis in KRAS/BRAF WT metastatic colorectal cancer patients treated with first-line FOLFOX/XELOX chemotherapy.

European journal of cancer (Oxford, England : 1990) - 1 Jul 2014

Alonso-Espinaco Virginia, Cuatrecasas Miriam, Alonso Vicente, Escudero Pilar, Marmol Maribel, Horndler Carlos, Ortego Javier, Gallego Rosa, Codony-Servat Jordi, Garcia-Albeniz Xabier, Jares Pedro, Castells Antoni, Lozano Juan José, Rosell Rafael, Maurel Joan

Abstract excerpt

INTRODUCTION: Chemotherapy is the principal treatment in metastatic colorectal cancer (mCRC) patients. RAC1b, a RAC1 spliced variant, is over-expressed in colorectal cancer (CRC), and impairs apoptosis by activation of nuclear-factor-KB. Since RAC1b has been associated with the BRAF(V600E) mutation, associated with poor prognosis in CRC, we evaluated the role of RAC1b expression as a predictor of chemotherapy...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

RAC1b overexpression correlates with poor prognosis in KRAS/BRAF WT metastatic colorectal cancer patients treated with first-line FOLFOX/XELOX chemotherapy.

Abstract excerpt

Topics

Related research